FPA 144

Drug Profile

FPA 144

Alternative Names: FPA144

Latest Information Update: 19 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 08 Aug 2017 Five Prime Therapeutics plans a phase I trial for Gastric cancer (Combination therapy) by the end of 2017
  • 17 Jul 2017 Five Prime Therapeutics plans a pivotal phase III trial for Gastric and Oesophageal cancer (First-line therapy, Combination therapy, Metastatic disease) in Japan and World in 2018
  • 17 Jul 2017 Phase-I clinical trials in Gastric and Oesophageal cancer (Late-stage disease, Monotherapy) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top